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ABSTRACT
Bone atrophy of the alveolar process is an important 
parameter in patients undergoing dental implants. Th ere 
are several methods for preserving the alveolar process, 
with the autologous bone graft as the gold standard. Other 
approaches include the use of allografts, xenografts and 
synthetic bone grafts.
 In recent years, the use of stem cells has increased in 
importance. Th e most common type of stem cells used are 
mesenchymal stem cells from various sources, including 
bone marrow, adipose tissue and dental pulp. Th e discov-
ery of induced pluripotent stem cells and the continued 
research on embryonic stem cells open new possibilities in 
this fi eld.  
However, further research is needed to optimise protocols 
for isolation, diff erentiation and transplantation of cells with 
or without appropriate scaff olds, and to determine the cor-
rect clinical and therapeutic implications.
Keywords: alveolar process atrophy, bone grafts, scaf-
folds, stem cells.
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SAŽETAK
Atrofi ja alveolarnog nastavka važan je parametar prilikom 
planiranja postupka ugradnje stomatoloških implantata. Po-
stoji više načina za očuvanje alveolarnog nastavka, pri čemu 
se autologni koštani graft smatra zlatnim standardom. Ostali 
pristupi očuvanja alveolarnog nastavka uključuju upotrebu 
alograftova, ksenograftova i sintetičkih koštanih graftova.
Poslednjih godina sve više dobija na značaju upotreba 
matičnih ćelija u ove svrhe. Najčešće korišćeni tip matičnih 
ćelija jesu mezenhimalne matične ćelije izolovane iz različi-
tih izvora, kao što su koštana srž, masno tkivo i zubna pul-
pa. Otkriće indukovanih pluripotentnih matičnih ćelija, kao 
i dalja istraživanja embrionalnih matičnih ćelija, otvaraju 
nove mogućnosti u ovoj oblasti.
Međutim, neophodna su dalja istraživanja da bi se opti-
mizovali protokoli za izolaciju, diferencijaciju i transplataciju 
matičnih ćelija sa ili bez upotrebe odgovarajućih skafolda i da 
bi se utvrdile njihove tačne kliničke i terapijske indikacije.
Ključne reči: atrofi ja alveolarnog nastavka, koštani 
graftovi, skafold, matične ćelije.
INTRODUCTION
Surgical repair of bone defects remains a major chal-
lenge for orthopaedic, reconstructive, dental and cranio-
facial surgeons, and usually occurs after a traumatic ex-
perience. The loss of bone can also occur from infection, 
neoplasm and congenital disorders. 
An important concern in dental medicine are defects 
that materialise after tooth extraction. Tooth extraction is 
one of the most common procedures, arising from several 
conditions, such as severe tooth decay, fractures, periodon-
tal diseases and endodontic lesions. The periodontium is a 
complex tissue composed mainly of periodontal ligament 
tissue (PDL), gingival tissue, alveolar bone and cementum. 
PDL has a deposit of somatic stem cells that could recon-
struct the periodontium, although its use in bone recon-
struction is still the period under investigation. For suc-
cessful implant placement into sites with missing dental 
units, adequate bone regeneration becomes vital in patient 
management.  
Alveolar process and dimensional changes of post-
extraction sockets 
The main aim of management is to prevent alveolar 
process atrophy,  that can occur after tooth removal. This 
atrophy starts developing during tooth eruption. The al-
veolar process supports the tooth socket and begins to re-
sorb following tooth loss  [1]. The volume and shape of the 
alveolar process is determined by the tooth formation, axis 
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of eruption and eventual inclination [2]. From early stud-
ies by Amler et al., we have a detailed description of unas-
sisted histological healing of alveoli in healthy humans [3]. 
When a tooth is removed, a clot forms and is gradually re-
placed by granulation tissue in the base and the periphery 
of the alveolus. After the first week, new bone formation 
is evident, with the osteoid matrix at the alveolus base as 
noncalcified bone spicules. In 38 days, this osteoid starts 
to mineralise from the alveolus base in a coronal direction, 
filling two-thirds of the alveoli. At this point, the first sign 
of a progressive resorption of the alveolar crest occurs. This 
process is followed by a continuous re-epithelialisation, 
which completely covers the socket 6 weeks after extrac-
tion. After additional bone fill develops, a maximum radio-
graphic density is achieved around the hundredth day. 
The usual outcome after tooth extraction includes is a 
reduction in the dimensions of the socket due to patho-
logic and traumatic processes that damage the bone walls 
of the socket. According to Araujo and Lindhe, notable 
osteoclastic activity occurred during the first eight weeks 
after tooth extraction, resulting in resorption of the crestal 
regions of both the buccal and lingual bone walls [4]. If fi-
brous tissue invades the empty socket, normal healing and 
osseous regeneration would be prevented, causing prob-
lems for future dental implants [5].
Alveolar process atrophy
Along with an incomplete healing of the socket, pro-
gressive bone resorption commences along the residual 
alveolar process. A reduction in both horizontal and verti-
cal directions has been observed over a 12-month period, 
with a predominant reduction occurring during the first 3 
months. This continual resorption leads to a narrower and 
shorter alveolar process [6]. Due to this effect, the alveolar 
process makes a positional change to a more palatal/lingual 
position. A study showed that the clinical loss in width (3.87 
mm) is greater than the loss in height, as assessed both clini-
cally (1.67-2.03 mm) and radiographically (1.53 mm) [2]. 
With bone grafting techniques, the horizontal and vertical 
dimensions of the alveolar process can be preserved. 
While alveolar atrophy is not a concern for most dentist 
and surgeons, knowledge about the healing process at the 
extraction sites, including the change in contour, as caused 
by bone resorption, is needed for treatment planning. In 
an effort to restore aesthetics and mastication function, 
procedures for bone regeneration by filling the extraction 
sockets have been developed. This has resulted in a satis-
factory alveolar process height and width, thus providing 
sufficient alveolar bone volume for dental implants.
BONE GRAFTS
During dental procedures, large bone defects can be 
created, which can cause problems associated with aes-
thetics, function, the healing process, and even jaw bone 
stability. The application of several materials to the area 
around these bony defects aids bone regeneration and 
eliminates the defects or limits their size. These materials 
may also prove useful in the regeneration of periodontal 
tissues, the filling of bone defects around an implant, and 
the augmentation of a deficient alveolar ridge [7].
Bones can regenerate from bone grafts. Bone grafting 
is a surgical procedure that replaces missing bone with 
material from the patient’s own body, or from an artificial, 
synthetic or natural substitute. As natural bone grows, the 
graft material is usually completely replaced, resulting in a 
fully integrated region of new bone. Clinical outcomes of 
bone grafting depend on the bone defect and extension, 
structural properties of the grafting material and the im-
munologic reaction of the host [8].
The bone grafts should be sterile, non-toxic, non-an-
tigenic, biocompatible and easy to use. Other important 
properties of bone grafts include the following [9-12]: 
1. Oosteointegration (This is the ability to chemically 
bond to the surface of bone without an intervening layer 
of fibrous tissue); 2. Osteoconduction (this is the ability 
to support the growth of bones as a scaffold on which 
bone cells can proliferate; osteoblasts from the margin of 
defect are grafted and utilised as the bone graft material 
as a framew ork upon which to spread and generate new 
bone); 3. Oosteoinduction (This is the ability to induce 
proliferation and differentiation of the MSCs from sur-
rounding tissues to an osteoblastic phenotype; Stimu-
lating the osteoprogenitor cells to differentiate into os-
teoblasts is needed, which begins the formation of new 
bone); 4. osteopromotion (This is the enhancement of 
osteoinduction without having any of the osteoinductive 
properties); and 5. Osteogenesis (Tthe graft material is a 
reservoir of MSCs and progenitor cells that can form new 
bone). The interaction between the graft and the sur-
rounding host bone is very important and is the subject 
of many researchers. Although some grafts will merely 
act as space fillers, the ideal graft will be osseoconductive 
and osseoinductive [13].  
Bone formation is a complex process that begins with 
the recruitment and proliferation of osteoprogenitor cells 
that are then differentiated into osteoblasts, with subse-
quent osteoid formation and matrix mineralisation. Their 
ability to attach to a scaffold surface is an important part 
in the development of new tissue. An ideal bone graft aug-
ments this osseous healing by providing a cellular milieu 
for new bone formation and a structural framework during 
healing [14]. A bone graft should not support local patho-
gens or cross-infection and should be resorbable, micropo-
rous and easy to handle.
Cancellous grafts have the highest concentration of 
osteogenic cells, and the particulate form of these grafts 
has the greatest cell survival ability, due to better diffusion 
and rapid revascularisation. These grafts must completely 
undergo a two-phase mechanism of graft healing. Osteo-
blasts that survive transplantation proliferate and form 
osteoid. This process is active in the first 2 to 4 weeks, 
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Allogenic bone grafts (allografts)
Allografts are an alternative to autografts. Different 
sources for bone harvesting can be used, such as and in-
cludebone from living or post-mortem donors. The graft 
may be fresh or fresh-frozen bone, freeze-dried allograft 
(FDBA) or decalcified freeze-dried bone allograft (DFD-
BA) and is considered a good source  of bone morphogenic 
protein. The American Association of Tissue Bank stan-
dards require that all donors be screened, serologic tests be 
performed, and all specimens be sterilised and verified by 
culture prior to release [13].
The increasing number of grafting procedures and the 
disadvantages of current autograft and allograft treatments 
(limited graft quantity, risk of disease transmission) drive 
the need for alternative methods to treat bone defects [19]. 
Synthetic bone graft (alloplastic grafts)
The use of synthetic bioactive bone substitute materials 
is of increasing importance in modern dentistry, as alter-
natives to autogenous or allogenic bone grafts. Due to the 
shortcomings of the decellularised, deproteinated, biologi-
cal materials, the quest for a synthetic material with many of 
the properties of decalcified, decellularised bone has been 
conducted. Its positive attributes include avoiding a second 
surgical site with less risk for patient morbidity and minimal 
risk of transplant rejection. Their physical properties can be 
manipulated and may be used in combination with bone-
promoting molecules to enhance the effect [12, 20]. How-
ever, they possess only two properties of an ideal bone graft 
material, osteointegration and osteoconduction. Most syn-
thetic bone grafts are biocompatible, show minimal fibrotic 
reaction, undergo remodelling and have similar strength to 
the cortical/cancellous bone being replaced.  
Various alloplastic bone substitution materials of differ-
ent origins, chemical composition, and structural properties 
have been investigated over the years. The materials com-
monly used are ceramics, polymers or composites. These al-
loplastic materials are either absorbable or non-absorbable 
and are naturally derived or synthetically manufactured [21]. 
Various types of biomaterials (minerals and non-mineral 
based materials and natural and artificial polymers) with 
different characteristics have been used to study ossification 
and bone formation. Calcium phosphate ceramics include a 
variety of ceramics, such as hydroxyapatite, tricalcium phos-
phate, and calcium phosphate cement. These mentioned ce-
ramics have either excellent biocompatibility, bone bonding 
or bone regeneration properties [22]. 
Xenogrograft  (heterografts)
Xenografts or heterografts are bone grafts from a spe-
cies other than human, such as bovine bone, which can 
be freeze-dried or demineralised and deproteinised. Xe-
nografts are usually only distributed as a calcified matrix. 
Attempts at xenograft transplantation (the transmission 
and the definitive amount of bone formed is related to the 
quantity of osteoid formed in phase one. Phase two starts 
at around the second week after grafting, and although it 
peaks in intensity at approximately 4 to 6 weeks, it contin-
ues until the graft matures. The initiation of phase two is 
marked by osteoclastic cell activity within the graft. Osteo-
clasts remove minerals, forming Howship’s lacunae along 
the trabeculae. This resorptive process exposes the extra-
cellular matrix of the bone, which is the natural location of 
the bone-inductive glycoprotein (BMP). Exposure of BMP 
initiates an inductive process characterised by chemotax-
is of the mesenchymal stem cells, proliferation of cells in 
response to mitogenic signals, and differentiation of cells 
into osteoblasts. Inducible cell populations may be local or 
distant from the graft site. 
Examples of local cell populations that may contribute 
to the graft include osteoprogenitor cells in the graft endos-
teum, stem cells of the transplanted marrow, or cells in the 
cambium layer of adjacent periosteum. Additional induc-
ible pluripotent cells may arrive at the graft site with bud-
ding blood vessels. During phase two, there is progressive 
osteoclastic resorption of phase one osteoid and nonviable 
graft trabeculae. This  continues to expose BMP, which 
perpetuates the differentiation of osteoblasts, leading to 
the formation of mature vascular osteocyte-rich bone [15]. 
Based on their bone of origin, grafts can be divided into 
four categories: autografts, allografts, alloplastic grafts and 
heterografts [16].
Autologous bone grafts (autografts)
The treatment of bone defects and preservation of the 
socket include autografting and allografting cancellous 
bone. The intraoral or extraoral autogenous bone graft is 
readily available and is the first choice of bone grafting ma-
terial for many clinicians. Autologous bone grafting usu-
ally harvests bone from the non-essential bones, such as 
the iliac crest, mandibular symphysis or anterior mandibu-
lar ramus, maxilla, cranium, tibial plateau and ribs. The 
shape, form, and volume of the graft procured are linked 
to the defect to be reconstructed. This is considered as a 
gold standard. Essentially, this graft has less risk of graft 
rejection or other immunological resistance, provides a 
scaffold for osteoconduction, growth factors for osteoin-
duction and progenitor cells for osteogenesis, and permits 
a fast angiogenic in-growth of vessels [17,18]. The main 
advantages of autogenous bone graft are biocompatibility, 
sterility and availability. However, there are several limita-
tions, including limited availability of bone, high surgery 
cost and post-operational morbidity, such as blood loss, 
wound complications and chronic pain.
All bones require blood supply in the transplanted 
site. Depending on the transplant site and graft size, an 
additional blood supply may be required. For these types 
of grafts, the extraction of the periosteum parts and ac-
companying blood vessels with the donor bone is required. 
This kind of graft is known as a free flap graft [8].
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of living organs, tissues, or cells from one species to an-
other) were first performed in the early twentieth century. 
Today, the relative shortage of human organs and tissue 
available for transplantation has amplified interest in xe-
nografts as alternatives to human-tissue transplants. Xe-
nografts are often used as scaffold and allow for ingrowth, 
and sometimes replacement, by host tissue while providing 
structural support for deficient tissue. Although the obvi-
ous advantage of xenotransplantation is the almost infinite 
amount of nonhuman animal tissue that might be consid-
ered for transplantation, its major disadvantage is the risk 
of cross-species disease transmission.
Of all the grafts, bone autografts give the best results. 
However their use is limited because a second concurrent 
surgical procedure is required. Therefore, the aforemen-
tioned synthetic substitute materials are used instead, and 
bone regeneration in areas with large bone defects is sat-
isfactorily accomplished. Successful graft incorporation is 
defined as the ability of the graft and surrounding tissues to 
function and maintain mechanical integrity [8, 23].
STEM CELLS
One tissue engineering method proposes tissue regen-
eration with the help of molecules, cells or a combination 
of these with biocompatible materials to ensure support 
and enhance physiological healing processes. Tissue engi-
neering may provide functional substitutes for native tis-
sue to serve as grafts for implantation.
Cells are described as pluripotent if they can form all 
the cell types of the adult organism. These cells are em-
bryonic stem (ES) cells and induced pluripotent stem (iPS) 
cells. Multipotent stem cells can form all the differentiated 
cell types of a given tissue, for example, mesenchymal stem 
cells. In some cases, a tissue contains only one differenti-
ated lineage, and the stem cells that maintain the lineage 
are described as unipotent, .for example, skin stem cells. 
By definition, a stem cell is characterised by its ability 
to self-renew and to differentiate along multiple lineage 
pathways. Bone marrow contains a large population of 
multipotent stem cells that are undifferentiated, which are 
known as stromal cells or mesenchymal stem cells (MSCs). 
They can be differentiated into several cell types, including 
osteocytes, chondrocytes, adipocytes and hematopoietic-
supportive stroma cells. This ability has been well proven. 
MSCs can be isolated from the bone marrow, cultured in 
vitro and implanted into bone defects to repair bone loss. 
These cells could be distinguished from the hematopoietic 
elements in the marrow by their high adherence to the sub-
strate plastic in tissue culture flasks. 
Historically, the use of MSCs in osteogenesis was initi-
ated by Friedenstein et al. in the 1970s [24, 25] and later 
by Kuznetsov et al. in 1989 [26], who were among the first 
researchers experimenting with MSCs transplantation be-
neath the renal capsule in mice and creating growths  in 
diffusion chambers in vivo in monolayer culture. Kuznets-
ov et al. showed that bone formation was characterised 
with lamellar, long trabeculae and abundant haematopoi-
esis. However, this study was limited to kidney transplants. 
Goshima et al. (1991) postulated that a composite of MSCs 
and ceramics, used as a delivery vehicles for these cells, 
contributes to accelerated and massive osseous repair [27]. 
This was shown by harvesting bone marrow cells from rats 
that were later introduced into tissue culture, and then the 
cells were mitotically expanded, passaged and placed on 
small cubes of porous calcium phosphate ceramics.  These 
samples were grafted in the subcutaneous sites of syngenic 
rats. Bone formation was observed as early as 2 weeks. The 
study concludes that while bone graft substitutes, such as 
calcium phosphate ceramics, are biocompatible and osteo-
conductive, ceramics do not induce bone formation. Only 
when such substitutes are combined with MSCs can bone 
formation be observed in the pore regions of the ceramics, 
in close association with the host vasculature. Kuznetsov et 
al. (1997) extended the experimentations by showing that 
individual human MSCs have osteogenic potential [28]. 
They transplanted human MSCs into the subcutaneous 
space of immunodeficient mice within vehicles containing 
hydroxyapatite-tricalcium phosphate ceramic and then 
proved that after 8 weeks, the transplants derived their 
bone from the human donor cells. Currently, this type of 
experiment is regular procedure for evaluating the osteo-
genic potential of stem cells in vivo [29].
The characteristics of an optimal stem cell include the 
following: no immunorejection, no graft-versus-host dis-
ease, no tumorigenicity, immediate availability, availability 
in pertinent quantities, controlled cell proliferation rate, 
predictable and consistent osteogenic potential, and con-
trolled integration into the surrounding tissue[10]. 
MSCs have been shown to heal bone defects in an auto-
loguous setting. Allogenic donor-derived MSCs present an 
attractive alternative to using autologuous cells. By using 
donor-derived cells, the need for harvesting and expanding 
cells for each patient is eliminated. Because billions of cells 
may be expanded from an individual donor, many devices 
can be created from rigorously tested and qualified cells. 
An allogenic MSC-based bone regeneration constructs for 
the augmentation and repair of alveolar bone were devel-
oped by several researchers. As demonstrated by a long-
term study, the histological evaluation of grafts in human 
mandibles after three years show that the regenerated 
bone is qualitatively a compact type, rather than a cancel-
lous (spongy) type that is physiological for the area. This 
was explained by the fact that grafted stem cells did not fol-
low the local signals of the surrounding spongy bone [30]. 
New research shows that low-intensity pulsed ultrasound 
stimulation could be a positive influence on osteogenic 
differentiation of the human alveolar bone-derived mes-
enchymal stem cells, that can be used in tooth tissue engi-
neering [31]. However, as some studies claim, researchers 
with MSCs need to establish more predictable outcomes 
and better long-term prognosis  to be considered a first-
choice treatment [32-35].
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An alternative to bone marrow-derived mesenchymal 
stem cells are the periodontal ligament stem cells (PDLSc) 
and the dental follicle cells (DFCs), which represent a new 
approach in reconstructive dentistry for the treatment of 
damaged periodontium. Restoration of lost periodontium 
is a challenge because alveolar bone, cementum and peri-
odontal ligament need to be restored to their original form. 
More research is needed to explore their true potential, al-
though some progress has been made by several research 
groups [36-40].  
THE IMPORTANCE OF SCAFFOLDS
The number of surgical procedures correcting bone 
defects use autografts, allografts or metallic and ceramic 
implants, each with its own drawbacks, including donor 
site morbidity, pathogen transmission, and mismatch-
ing material properties with the native bone, respectively. 
As an alternative to these procedures, tissue engineering 
has emerged to create de novo tissue by growing cells on 
three-dimensional (3D) scaffolding [41, 42]. Scaffolds play 
an important role in dental regenerative medicine because 
conventional tissue replacements, such as autografts and 
allografts, have a variety of problems that cannot satisfy 
high performance demands necessary for today’s patients. 
Bone is a nanocomposite that consists of a protein-based 
soft hydrogel template (collagen, non-collagenous proteins 
(laminin, fibronectin, and vitronectin), water and hard in-
organic components (70% of the bone matrix is composed 
of nanocrystalline hydroxyapatite). This self-assembled 
nanostructured extracellular matrix (ECM) in bone closely 
surrounds and affects the mesenchymal stem cells, osteo-
blasts, osteoclasts and fibroblast adhesion, proliferation 
and differentiation [43].
Investigators are searching for the “ideal scaffold” to fa-
cilitate the growth, integration and differentiation of stem 
cells [44]. The best scaffold for engineered tissue should be 
the ECM of the target tissue in its native state because ECM 
components specifically modulate MSC adhesion, migra-
tion, proliferation and osteogenic differentiation [45, 46]. 
Scaffolds are artificial structures that should mimic the mor-
phologic structures and function of the surrounding tissue. 
Scaffolds allow cell attachment and migration, deliver and 
retain cells and biochemical factors, enable diffusion of the 
vital cell nutrients and expressed products [47].
Cell and tissue response to a scaffold depends upon the 
composition of the scaffold, its surface microstructure, and 
three-dimensional architecture. Scaffolds should provide 
void volume for vascularisation and new tissue formation 
during remodelling, provide the shape and mechanical sta-
bility to the tissue defect and provide rigidity and stiffness to 
the engineered tissues [45]. Appropriate porosity and pore 
structure is needed to accept and organise the types of cells 
and tissues that regenerate [48]. Mechanical properties that 
are appropriate for the cells and their macro- and microen-
vironments are also needed. The cellular microenvironment 
at the interface between tissue and scaffold is extremely im-
portant and must be created to either recruit cells into the 
scaffold or allow cells to be seeded or transplanted for repair. 
Scaffolds allow cell attachment and migration, deliver and 
retain cells and biochemical factors, enable diffusion of the 
vital cell nutrients and expressed products, and should pro-
mote healing and should be easily fabricated [49-51].
Biocompatibility is of the utmost importance to pre-
vent adverse tissue reactions. Because the host cells will 
interact with the scaffold, biodegradability is a must  to 
facilitate constructive remodelling, which is characterised 
by scaffold degradation, cellular infiltration, vascularisa-
tion, differentiation and spatial organisation of the cells, 
and replacement of the scaffold by the appropriate tissues 
[52]. Material scientists can now fabricate biocompatible 
scaffolds with a wide range of physical parameters, combin-
ing mechanical integrity with high porosity to promote cell 
infiltration and angiogenesis. Currently proposed scaffolds 
include those made of inorganic materials, organic or syn-
thetic polymers, or mixed materials (composite scaffolds). 
These materials include natural polymers (collagen, chitin, 
alginate), synthetic polymers (Polyglycolic acid (PGA), Poly 
(lactic-co-glycolic acid) (PLGA), Poly (lactic acid) (PLA)), 
metals (titanium, nitinol), and ceramics, such as calcium 
phosphates (hydroxyapatite, tricalcium phosphate], calcium 
sulphates, and biological glass [52, 53]. The biomaterials 
need to be compatible with the biomolecules and amenable 
to an encapsulation technique for controlled release of the 
biomolecules with retained bioactivity [45]. Natural materi-
als offer a high degree of structural strength, are compatible 
with cells and tissues and biodegradable, but are often dif-
ficult to process and afflicted with the risk of transmitting 
animal-associated pathogens or provok ing an immunore-
sponse. Synthetic polymers provide excellent chemical and 
mechanical properties and allow greater control over the 
physicochemical characteristics, such as molecular weight, 
configuration of polymer chains, and the presence of func-
tional groups. Hydrogels offer numerous properties includ-
ing high biocompatibility, a tissue-like water content and 
mechanical characteristics similar to those of native tissue. 
An ideal scaffold should combine the best properties of each 
of these groups of biomaterials [44, 54, 55].
Experiments with cell-free scaffolds are especially at-
tractive because they have an easier handling process 
that eliminates the issues associated with the use of stem 
cells, their expansion in vitro, stor age and shelf-life, cost, 
the immunoresponse of the host and transmission of dis-
eases [53, 56]. However there are some disadvantages in 
this method: the cells may have low survival rates, the cells 
might migrate to different locations within the body, lead-
ing to aberrant mineralisation patterns. A solution may be 
to apply the cells together with a scaffold. This would help 
to position and maintain cell localisation [53, 57].
The paradigm of bone tissue engineering procedures is 
in the isolation and expansion of mesenchymal stem cells 
(MSCs) from the patients and their seeding onto porous 
biodegradable matrices, and scaffolds. Scaffold morphol-
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ogy, in terms of interconnectivity, pore-size and shape is 
a crucial point for stem cell-biomaterial interaction. High 
porosity and adequate pore-size are necessary properties 
for increasing the surface area available for cell attachment 
and tissue in-growth in order to facilitate the uniform dis-
tribution of cells and the adequate transport of nutrients. 
Small pores on the macropore surface of the scaffolds may 
also be helpful to improve the biological performance of 
the porous scaffolds and promote more favourable biore-
sorption of the material [50, 58]. 
During the in vitro culture period, stem cells are gener-
ally exposed to signalling molecules (growth factors and 
other osteoinductive molecules), supplied as soluble fac-
tors and/or released by the scaffold, to drive MSCs toward 
the osteogenic lineage differentiation. This engineered tis-
sue is implanted into the damaged site to regenerate the 
new bone as the scaffold degrades [59]. Implantation of in 
vitro-expanded MSCs within the appropriate scaffold re-
sulted in bone regeneration in various animal models. The 
supporting scaffold plays a very important part by provid-
ing an anchorage point for cells. 
 The use of scaffolds with different types of parti-
cles offers the advantage of perfectly adapting to the shape 
of the defect without interfering with the vascularisation 
process. Biological granular scaffolds can stimulate vascu-
larisation and tissue integration because of the appropriate 
spaces between the particles of the inorganic material. Us-
ing granular material also accelerates the scaffold resorp-
tion process and the replacement of the inorganic material 
with newly formed bone. Scaffolds containing crystalline 
beta-tri-calcium phosphate have been proven to lack lo-
cal and systemic toxicity. Its granular consistency provide 
an optimal osteoconductive environment for the develop-
ment of bone tissue. Tricalcium phosphate is extremely 
hydrophilic, making it easily insertable inside the defect. 
Tri calcium phosphate scaffolds ensure rapid resorption, 
which is an advantage for small and medium size defects, 
and they also release calcium and phosphate ions, assuring 
rapid mineralisation of the newly formed tissue. 
Porous ceramic scaffolds have already been noted as 
the most suitable material for reproducing the structural 
integrity of ossified tissues. When combined with the bio-
active attributes of calcium phosphate, hydroxyapatite, 
bioactive glass, or other similar ceramics, the composite 
material can support progenitor cells and mimic the natu-
ral characteristics of bone [52].
. 
LATEST RESULTS AND ACHIEVEMENTS
The emerging field of regenerative medicine will re-
quire a reliable source of stem cells, biomaterial scaffolds 
and cytokine growth factors. One study showed massive 
bone formation when autologous mesenchymal stem cells 
placed on TCP scaffolds were implanted in the alveolar 
sockets on a rat animal model. This study used a large 
number of osteoprogenitor cells on a scaffold, which has 
proven to accelerate the osteogenesis process, and showed 
that a concentration of 5x104 cells/ml can induce bone 
formation, whereas a concentration of 0,5  - 1 x 106 cells/
ml did not show satisfactory results. The study concludes 
that implantation of autologous mesenchymal stem cells 
on specific scaffolds will augment bone repair [60]. New 
studies have suggested that transplanted bone-marrow 
derived MSCs can deliver new mitochondria to damaged 
cells, thereby rescuing the aerobic metabolism [61].
Adipose tissue represents an alternative source of adult 
stem cells with the ability to differentiate along multiple lin-
eage pathways. To identify this isolated, plastic-adherent, 
multipotent cell population, these cells are called adipose-
derived stem cells (ASCs) according to the International 
Fat Applied Technology Society. The evidence supporting 
the claims that adipose tissue contains multipotent pro-
genitor cells start from an inborn metabolic error, the pro-
gressive osseous heteroplasia (POH), where ectopic bone 
can be formed within the subcutaneous adipose layer of 
the skin in children. Histological analysis shows the pres-
ence of osteoblasts, chondrocytes and adipocytes. This im-
plies that adipose-derived stem cell can differentiate along 
adipogenic, chondrogenic and osteogenic lineages. 
Adipose tissue derives from the mesodermal layer of 
the embryo and develops both pre- and postnatally. Mac-
roscopically, at least 5 different types of adipose tissue ex-
ist: bone marrow, brown, mammary, mechanical and white 
[62]. A study showed that in humans, subcutaneous white 
adipose tissue in the arm had a greater number of stem 
cells compared to the thigh, abdomen and breast [63]. The 
ASCs maintain their telomere length with progressive pas-
sage in culture, however with prolonged passage for more 
than 4 months, human ASCs can undergo malignant trans-
formation [64]. The greatest advantage of using ASCs is 
that it can be obtained repeatedly in large quantities under 
local anaesthesia with minimal patient discomfort. 
Beside autologous ASCs, the use of allogeneic ASCs is 
also important. Studies have demonstrated that the pas-
sage of human ASCs reduces the expression of surface his-
tocompatibility antigens and no longer stimulates a mixed 
lymphocyte reaction when co-cultured with allogeneic pe-
ripheral blood monocytes [65, 66]. This profoundly affects 
the field of regenerative medicine. A study showed that after 
a 3 month healing period, the addition of ASCs to platelet-
rich plasma (PRP) enhanced the amount of n-ewly formed 
dog alveolar bone [67], and other studies came to thesimilar 
conclusions [68, 69]. One study compared the use of ASCs 
and autogenous bone grafts in dogs, bone formation in the 
maxillary alveolar cleft was higher in the autograft group 
[70]. More long-term experiments examining the safety of 
ASCs transplantation in appropriate animal models are re-
quired before advanced studies in patients. 
Another potential source for tissue engineering is em-
bryonic stem cells (ESCs). They are harvested from the 
inner cell mass of blastocysts. Their pluripotent charac-
teristics enable unlimited self-renewal and differentiation 
into all cell types. A challenge that needs to be addressed 
is their tumorigenic potential. Therefore, removing the re-
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maining undifferentiated ES cells from the newly formed 
tissue before implantation is crucial. Further research is 
needed to develop efficient methods to direct ES cells into 
therapeutically desired cell lineages, such as osteoblast, 
while eliminating the pluripotent cells.   
   The latest trend in tissue engineering is using nuclear 
reprogramming to convert a somatic cell type into a differ-
ent, unrelated one through a switch of the gene expression 
pattern, resulting in the generation of an embryonic stem 
cell-like pluripotent cells by ectopic overexpression of only 
four genes in human fibroblasts. These cells are called in-
duced pluripotent stem cells (iPSCs) [71-73]. This research 
showed that somatic cells, such as fibroblasts or adipocytes, 
can be directly converted to clinically relevant cell types 
after ectopic delivery of factors which are involved in the 
embryonic development of the targeted cell type. The as-
sumption is that factors responsible for the maintenance of 
the pluripotent state in embryonic stem cells (ESCs) could 
induce pluripotency in somatic cells after ectopic overex-
pression.  Kazutoshi Takahashi and Shinya Yamanaka iden-
tified four factors Oct4, Sox2, Klf4 and c-Myc as being suf-
ficient to reprogram mouse embryonic fibroblasts (MEFs) 
into a morphology highly comparable with embryonic stem 
cells, which they named iPSCs [74]. iPSCs could maintain 
their self-renewal when cultured under ESC conditions 
and differentiate into cells of all three germ layers [75-77], 
which proved that they are nearly indistinguishable from 
ESCs. More recent investigations convincingly support the 
osteogenic potential of hESCs and iPSCs in vivo [78, 79]. 
Arpornmaeklong and co-workers derived MSCs from the 
hESC line BG01, characterised by the expression of MSC-
specific surface antigens, and further differentiating them 
into adipogenic, chondrogenic and osteogenic tissue [78]. 
Transplanting iPS cells uses the patient’s own cells, 
eliminating the need for immunosuppression. Discovering 
how the pluripotent state can be efficiently induced and 
maintained by treating cells with pharmacologically active 
compounds, rather than genetic manipulation, is an im-
portant goal [80]. 
As new surgical techniques develop for replacing non-
functional tissues or organs, the need for more artificial 
means of organ transplants or tissue regeneration will arise. 
A well-defined pathology, such as alveolar bone atrophy, 
requires further advances in the field of bone regeneration 
using stem cells to generate new tissue or regenerate re-
sidual tissue. Development in this field will benefit several 
branches in medicine and dentistry. Techniques for im-
proved growth rate, extent and strength of n-ewly formed 
bone must be developed in concordance with increased 
clinical application. Most importantly, researchers need to 
ensure that any tumorigenic potential is eliminated.
CONCLUSION AND FUTURE DIRECTIONS
Bone tissue engineering can overcome the drawbacks 
of traditional bone graft materials and offers a novel way 
for bone repair and regeneration. Scientists have been ac-
tively investigating the ideal cell source to regenerate and 
repair bone for the last four decades. More than 300 ar-
ticles [81] on bone regeneration using stem cells in animal 
models have been published. However, only a few studies 
include human subjects [82]. MSCs derived from the adult 
bone marrow provide an exciting and promising stem cell 
population for bone repair. The disadvantages of MSCs 
are the limited availability of cells for therapy and the non-
specific cell surface markers. Therefore, specific markers 
need to be identified for easier detection in laboratories.  E 
SCs are also a potential source and have an additional ad-
vantage of unlimited division and pluripotency. However 
a reproducible protocol to ensure that ESCs differentiate 
into functional bone needs to be developed.
 ESCs studies need to overcome ethical issues, immune 
responses and tumorigenic potential. ESCs represent an 
innovative treatment for many disease conditions, but still 
require rigorous evaluation for use in clinical applications. 
IPS cells are currently the most exciting and promising cell 
population, with ASCs a close second. Both cells popula-
tions are at the apex of their popularity within the scientific 
community, as a supply of readily available cells can truly 
push the field of regenerative medicine. The field of regen-
erative medicine should not be entrenched in only stem 
cells but also expand knowledge in the use of bone grafts 
and scaffolds. This should be used in a complementary 
way, if we strive for maximum results in the treatment of 
diseases. 
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Treatment initiation time for dialysis
supportive therapy
In patients with AKI, it is necessary to assess the sever-
ity of injury and the presence of absolute indications for 
treatment with renal replacement therapy (RRT) (dialysis 
supportive therapy). Absolute indications for initiation of 
dialysis treatment include: serum urea concentration ≥ 36 
mmol/L, complications of uraemia (uremic encephalopa-
thy, uremic pericarditis), resistant hyperkalaemia (K+ > 6.5 
mmol/L with or without electrocardiographic changes), 
hypermagnesaemia (Mg2+ ≥ 4.0 mmol/L and absence of 
deep tendon reflexes), severe metabolic acidosis (arterial 
blood pH ≤ 7.15) and volume overload (pulmonary oe-
dema) resistant to diuretics in the presence of oligoanuric 
AKI [40]. In patients with severe AKI (RIFLE-F or AKIN 
III), initiation of dialysis supportive therapy is to be con-
sidered, and increased monitoring and treatment is recom-
mended in those with mild/moderate AKI (RIFLE-R or I, 
AKIN I or II). Prior to making a decision to initiate RRT 
treatment in patients with mild or moderate renal injury, 
the treatment objectives, primary diagnosis, severity of the 
patient’s clinical condition, renal functional reserve and 
the need to prevent development of complications should 
be taken into account. In patients with sepsis (high catabo-
lism), there is a potential benefit of early initiation of di-
alysis treatment [40]. When making the decision to start 
dialysis treatment with supportive therapy, clinical condi-
tions that adversely affect renal function in ICU patients, 
such as increased intra-abdominal pressure, mechanical 
positive pressure ventilation and use of nephrotoxins and 
radiocontrast agents, should be considered [40].
Selecting modes of dialysis supportive therapy 
Patients with AKI are treated with numerous dialysis 
modalities, employed to remove uremic toxins and sub-
stances from the blood using mechanisms of diffusion 
(peritoneal dialysis, standard haemodialysis, slow low effi-
ciency dialysis [SLEDD], continuous veno-venous haemo-
dialysis), convection (intermittent haemofiltration, contin-
uous veno-venous haemofiltration [CVVHF], continuous 
veno-venous high-volume haemofiltration [HVHF]), a 
combination of diffusion and convection (intermittent hae-
modiafiltration, slow low-efficiency diafiltration [SLEDDf], 
continuous veno-venous haemodiafiltration [CVVHDF]) 
and adsorption (continuous veno-venous haemodiafiltra-
tion using a polymethylmethacrylate membrane haemofil-
ter [PMMA-CHDF]) [41-49]. 
Intermittent haemodialysis is performed in patients 
who are haemodynamically stable, with high levels of 
nitrogen and severe hyperkalaemia, and in patients with 
an increased risk of bleeding. Individual session doses 
for conventional intermittent (3 times per week) and en-
hanced intermittent (6 time per week) haemodialysis are 
single pool Kt/V index ≥ 1.2 [47, 48]. Intermittent hae-
modialysis has little impact on most of the major inflam-
matory cytokines. Hybrid modes of dialysis therapy, such 
as slow low-efficiency dialysis (SLEDD), provide excel-
lent clearance of low molecular weight uraemic toxins, 
moderate clearance of medium molecular weight uremic 
toxins and good haemodynamic stability of patients [47, 
48]. Individual session doses for conventional SLEDD (3 
times per week for 6-12 hrs) and enhanced SLEDD (6 
times per week for 6-12 hrs) are a single pool Kt/V in-
dex ≥ 1.2 (single pool Kt/V index = 1.2-1.4) [47, 48]. SSC 
(Surviving Sepsis Campaign) guidelines recommend that, 
in the absence of haemodynamic instability, intermittent 
and continuous dialysis treatment modalities should be 
equally considered [49]. Haemodynamically unstable pa-
tients (septic shock) in intensive care units suffering from 
AKI, with multiple organ dysfunction syndrome, elevated 
levels of serum cytokines (interleukin-6 concentrations ≥ 
1000 pg/mL), increased catabolism and hypervolaemia 
require treatment modalities of continuous renal replace-
ment therapy (CRRT) [41-49]. 
Most immune system mediators are substances of me-
dium molecular weight (5-50 kD), soluble in water and 
removable using continuous renal replacement modali-
ties. The standard dialysis dose in continuous veno-venous 
haemofiltration (CVVHF) and continuous veno-venous 
haemodiafiltration (CVVHDF) is 20-30 mL/kg/h, while 
in patients with sepsis and acute kidney injury the dose of 
continuous dialysis modality should be 35 mL/kg/h [41-45, 
50, 51]. High-volume continuous veno-venous haemofil-
tration (HVHF) is used for the removal of pro- and anti-
inflammatory mediators, due to the high convective trans-
port, at > 35 mL/kg/h. It may be used continuously, with an 
ultrafiltration rate of 50-70 mL/kg/h (35-80 mL/kg/h) over 
24 hours, or as pulse high-volume haemofiltration, with 
an ultrafiltration rate of 85-100 mL/kg/h (100-120 mL/
kg/h) over 4-8 hours, followed by the standard dose after-
wards [48-50]. High-volume haemofiltration significantly 
reduces the concentration of inflammatory mediators and 
restores the balance between inflammatory syndrome and 
compensatory anti-inflammatory systemic responses [41-
45, 50, 51]. 
Continuous veno-venous haemodiafiltration with 
PMMA membrane (PMMA-CHDF) is administered within 
24 hours of developing septic shock, and it removes cytok-
ines via the adsorption process to the dialysis membrane 
matrix (i.e., cytokine adsorption to highly specific mem-
branes/membranes with high cytokine removal capacity). 
It is effective in the treatment of clinical conditions asso-
ciated with increased concentration of serum cytokines 
(interleukin-6 concentrations 6 ≥ 1000 pg/mL), such as 
septic shock, multiple organ dysfunction syndrome caused 
by sepsis, acute respiratory distress syndrome and severe 
acute pancreatitis [41-45, 50, 51]. The results of clinical 
trials (EUPHAS Study) show that PMMA-CHDF is more 
effective in cleansing blood of patients with severe sepsis 
and septic shock compared to PMX-DHP (Polymyxin-B di-
rect haemoperfusion), which plays an important part in the 
removal of endotoxin (lipopolysaccharide) from the blood 
of septic patients [41-45, 50, 51]. 
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Continuous modalities of dialysis supportive therapy 
should provide haemodynamic stability and homeostasis 
of the immune system. It provides an opportunity to use 
CRRT not only as supportive therapy, but also but also as 
a treatment to prevent injury progression and the devel-
opment of multiple organ dysfunction syndrome in septic 
patients [50, 51]. 
Conclusion
The early identification of patients at increased risk for 
developing acute kidney injury and timely implementation 
of an appropriate treatment plan can prevent the devel-
opment of acute kidney injury and reduce morbidity and 
mortality in septic patients. Haemodynamically unstable 
patients (septic shock) in intensive care units suffering 
from acute kidney injury, on mechanical respiration, with 
multiple organ dysfunction syndrome, elevated levels of 
serum cytokines, increased catabolism and hypervolaemia 
require treatment modalities of continuous renal replace-
ment therapy. Well-controlled, prospective, randomised 
clinical trials should more precisely determine the place 
and role of various modalities of dialysis therapy in pa-
tients with sepsis and AKI in intensive care units.
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